Theralugand is a solution containing a radioactive form of lutetium (177Lu) that is used for radiolabelling other medicines. Radiolabelling is a technique where a substance is labelled with a radioactive compound. Once the substance is radiolabelled with Theralugand, it then carries the radioactivity to where it is needed in the body (for example, the site of a tumour) to either treat a disease or obtain images to locate or diagnose an illness. Theralugand is never given directly to a patient. Theralugand contains the active substance lutetium (177Lu) chloride and is used to radiolabel medicines that have been specifically developed for use with lutetium (177Lu) chloride.
Therapeutic Indication
### Therapeutic indication Theralugand is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.
Therapeutic Area (MeSH)
ATC Code
V10X
ATC Item
其它治疗用放射性药物
Pharmacotherapeutic Group
Other therapeutic radiopharmaceuticals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| lutetium (177Lu) chloride | N/A | Lutetium Lu-177 |
EMA Name
Theralugand
Medicine Name
Theralugand
Aliases
N/ANo risk management plan link.
